Bifosfonatos en Odontopediatría: revisión de la literatura, protocolo de manejo y reporte de un caso clínico

Ingrid Báez Madrigal; Rubí  López Fernández; Jorge Pedro Téllez Rodríguez

doi:10.47990/alop.v11i2.278

Autores

Ingrid Báez Madrigal Instituto Nacional de Pediatría https://orcid.org/0000-0001-5725-8959
Rubí López Fernández Instituto Nacional de Pediatría https://orcid.org/0000-0002-4592-4309
Jorge Pedro Téllez Rodríguez Instituto Nacional de Pediatría

DOI:

https://doi.org/10.47990/alop.v11i2.278

Palavras-chave:

cirurgia maxilofacial, pediatria, bisfosfonato

Resumo

Atualmente, os bisfosfonatos são utilizados na população pediátrica diagnosticada com osteogênese imperfeita, distúrbios neuromusculares, displasia óssea, displasia fibrosa, osteoporose idiopática juvenil, doença de Crohn e distúrbios reumatológicos. A osteonecrose dos maxilares secundárias ao tratamento com bifosfonatos tornou-se uma complicação cada vez mais comum devido ao aumento do uso na população adulta. Quanto ao atendimento pediátrico, as informações são escassas. Este estudo apresenta o caso clínico de uma paciente do sexo feminino com diagnóstico de osteogênese imperfeita tipo III, tratada com múltiplas exodontias sob anestesia geral, após administração de amoxicilina 50 mg / kg 1 hora antes; devido à erupção anômala de caninos superiores e primeiros pré-molares, bem como persistência de caninos decíduos superiores e molares. Foram marcadas consultas de controle pós-operatório, onde apresentava processo de cicatrização adequado, sem dados de necrose maxilar. O objetivo é informar ao estomatologista como os bisfosfonatos atuam, os diagnósticos na população pediátrica tratada com esse medicamento e apresentar o protocolo de manejo desses pacientes. Realizou-se revisão integrativa nas bases de dados PubMed e Cochrane Library, os artigos foram selecionados de acordo com os critérios estabelecidos.

Referências

-Gasser JA, Kneissel M. Bone Physiology and Biology. En: Smith SY, Varela A, Samadfam R. Bone Toxicology. XII ed. Montreal, Canada. Springer International 2017:27-94.

- Dominguez L, Di Bella G, Belvedere M, Barbagallo M. Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology 2011;12:397-408.

DOI 10.1007/s10522-011-9344-5

- Batt RN, Hibbert SA, Munns CF. The use of bisphosphonates in children: review of the literature and guidelines for dental management. Australian Dental Journal 2014;59:9–19.

DOI: 10.1111/adj.12140

Bourgeois AB, Aubry-Rozier B, Bonafé L, et al. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. Swiss Med Wkly 2016;146:1

-Eghbali-Fatourechi G. Bisphosphonate therapy in pediatric patients. Journal of Diabetes & Metabolic Disorders 2014;13:109.

-Endo Y, Kumamoto H, Nakamura M, et al. Underlying Mechanisms and Therpeutic Strategies for Bisphosphonate-Related Osteonecrosis of the jaw (BRONJ). Biol.Pharm.Bull 2017;40:739-750.

-Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews 2016;10:1-71.

DOI: 10.1002/14651858.CD005088.pub4.

-Ngan K-K, Bowe J, Goodger N. The Risk of Bisphosphoate Related Osteonecrosis of the Jaw in Children. A Case Report and Literature Review. Dent Update 2013;40:733–738.

-Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–1491.

-Khan AA, Sandor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35:1391–1397.

-Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws 2009 update. J Oral Maxillofac Surg 2009;67:2–12.

-Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006;35:801–803.

- Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 2008; 37:196-200.

-Brown JJ, Ramalingam L, Zacharin MR. Bisphosphonate associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol (Oxf) 2008;68:863–867.

-Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F. Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 2008;153:719–720.

- Schwartz S, Joseph C, Iera D, Vu D-D. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series. J Can Dent Assoc 2008;74:537–542.

-Grier RL, Wise GE. Inhibition of tooth eruption in the rat by a bisphosphonate. J Dent Res 1998;77:8–15.

-Bradaschia-Correa V, Massa LF, Arana-Chavez VE. Effects of alendronate on tooth eruption and molar root formation in young growing rats. Cell Tissue Res 2007;330:475-485.

-Hiraga T, Ninomiya T, Hosoya A, Nakamura H. Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats. Calcif Tissue Int 2010;86:502–510.

- Lotwala RB, Greenlee GM, Ott SM, Hall SH, Huang GJ. Bisphosphonates as a risk factor for adverse orthodontic outcomes: a retrospective cohort study. Am J Orthod Dentofacial Orthop 2012;142:625–634.

-Ghoneima AA, Allam ES, Zunt SL, Windsor LJ. Bisphosphonates treatment and orthodontic considerations. Orthod Cranio- fac Res 2010;13:1–10.

-Hennedige AA, Jayasinghe J, Khajeh J, Macfarlane TV. Systematic Review on the Incidence of Bisphosphonate Related Osteonecrosis of the Jaw in Children Diagnosed with Osteogenesis Imperfecta. J Oral Maxillofac Res 2013;4(4):e1 Disponible en: http://www.ejomr.org/JOMR/archives/2013/4/e1/v4n4e1ht.pdf